Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 81,280 |
|
|||||
| News | - | ||||||
| Day High | 5.08 | Low High |
|||||
| Day Low | 4.92 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Puma Biotechnology Inc | PBYI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.035 | 0.70% | 5.025 | 11:30:09 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.92 | 4.92 | 5.08 | 4.99 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 969 | 81,280 | $ 4.98 | $ 404,495 | - | 2.13 - 7.73 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:30:48 | 7 | $ 5.02 | USD |
Puma Biotechnology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 241.04M | 48.21M | - | 235.64M | 21.59M | 0.45 | 11.16 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Puma Biotechnology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PBYI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.37 | 5.5206 | 4.92 | 5.17 | 262,221 | -0.345 | -6.42% |
| 1 Month | 5.28 | 6.055 | 4.92 | 5.44 | 398,729 | -0.255 | -4.83% |
| 3 Months | 4.95 | 7.73 | 4.14 | 5.76 | 603,009 | 0.075 | 1.52% |
| 6 Months | 2.45 | 7.73 | 2.13 | 5.15 | 449,018 | 2.58 | 105.10% |
| 1 Year | 2.80 | 7.73 | 2.13 | 4.62 | 310,280 | 2.23 | 79.46% |
| 3 Years | 10.01 | 11.95 | 1.60 | 4.42 | 386,040 | -4.99 | -49.80% |
| 5 Years | 32.80 | 35.27 | 1.60 | 8.70 | 676,066 | -27.78 | -84.68% |
Puma Biotechnology Description
| Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. |
